Predictive Kit to identify patients non responding to platinum therapy

Summary of the technology

Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types.

The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treatment at higher risk of developing drug resistance and disease progression. Drugs such as cisplatin, oxaliplatin and carboplatin are used to treat various types of worldwide common cancer, but resistance is a frequent event. Patient stratification based on tumor gene expression profile allows to personalize treatment reducing side effects and costs.

Details of the Technology Offer


10 gene signature to discriminate responders and non responders patients to platinum therapy in different tumors.


i) Disease: Epithelial Ovarian Cancer, Triple Negative Breast Cancer and potentially applicable to other cancer treatable with platinum.
ii) Sample: mRNA extracted from cancer cells
iii) Technology: any technique to quantify nucleic acids.


i) Gene expression quantification can be performed with high throughput, widespread techniques
ii) Applicability in different tumor types treatable with platinum
iii) Reduction of treatment costs
iv) Improvement of patients life quality by avoiding ineffective treatment and potentially serious, useless side effects.


Deep knowledge in oncology field and biochemical techniques, cancer cell lines models, sample availability for in house test.


Commercial partner interested in the development of the kit under license or co-development.

Intellectual property status

  • Patent already applied for
  • Patent application number :102019000000130

Attached documents

Related Keywords

  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Diagnostics, Diagnosis
  • Gene - DNA Therapy
  • Population genetics Technology
  • Remote diagnostics
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Oncology
  • Medical equipment
  • predictive biomarker
  • predictive kit

About National Cancer Institute CRO Aviano

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.


Never miss an update from LUCIA CORAL

Create your free account to connect with LUCIA CORAL and thousands of other innovative organizations and professionals worldwide


Send a request for information

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support